CRC Research Update — August 06, 2026
Today's colorectal cancer research highlights
metastatic
A collection of 142 issues
CRC Research Update — August 03, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 02, 2026
Today's colorectal cancer research highlights
Liquid Biopsy Detects ctDNA in 95% of Metastatic CRC Patients
Skip to content
The CRC Digest
▸ TREATMENT
Liquid Biopsy Detects ctDNA in 95% of Metastatic CRC Patients
A Japanese single-center study using Guardant360 CDx found circulating tumor DNA in 18 of 19 metastatic colorectal cancer patients, with a median turnaround time of 11 days and pathogenic alterations identified in 79%
Surgery After Disease Progression May Still Benefit Select Liver Metastasis Patients
Skip to content
The CRC Digest
▸ TREATMENT
Surgery After Disease Progression May Still Benefit Select Liver Metastasis Patients
A Japanese nationwide study analyzed patients from the Colorectal Cancer Liver Metastasis Database who received chemotherapy. (Annals of Surgical Oncology)
This content is informational only and does not constitute medical advice.
Always
Medicaid Expansion Linked to Lower Mortality in Metastatic CRC
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Medicaid Expansion Linked to Lower Mortality in Metastatic CRC
A SEER database analysis found that Medicaid expansion was associated with decreased mortality in patients younger than 65 diagnosed with colorectal cancer and synchronous liver metastasis. (Annals of Surgery)
This content is
First Patient Dosed in Phase 2 Trial of Oral KRAS G12D Inhibitor
Skip to content
The CRC Digest
▸ TREATMENT
First Patient Dosed in Phase 2 Trial of Oral KRAS G12D Inhibitor
Verastem Oncology has dosed the first patient in a phase 2 registration-directed trial of VS-7375, an oral KRAS G12D inhibitor, for KRAS G12D-mutated metastatic colorectal cancer. (BioSpace)
This content is informational
Liquid Biopsy Guides HER2 Therapy Rechallenge in Metastatic CRC
Skip to content
The CRC Digest
▸ TREATMENT
Liquid Biopsy Guides HER2 Therapy Rechallenge in Metastatic CRC
A study found that liquid biopsy can guide rechallenge with anti-HER2 therapy in patients with HER2-amplified metastatic colorectal cancer. (JCO Precision Oncology)
This content is informational only and does not constitute medical advice.
Always
CRC Research Update — July 31, 2026
Today's colorectal cancer research highlights
Case report: BRAF V600E-mutant metastatic CRC patient achieves prolonged response to combined BRAF and MEK inhibition
Skip to content
The CRC Digest
▸ TREATMENT
Case report: BRAF V600E-mutant metastatic CRC patient achieves prolonged response to combined BRAF and MEK inhibition
A 60-year-old male patient diagnosed in 2019 with BRAF-mutant metastatic CRC and peritoneal metastases experienced an extraordinary response to MEK inhibitor-based treatment. (Frontiers in Oncology)
This content